Key Highlights

  • Artrya has signed a five-year commercial agreement with HonorHealth, an Arizona health system, with a minimum contracted value of US$0.5 million.
  • HonorHealth is Artrya’s fifth US commercial customer and its first inbound customer secured outside its foundation customers and SAPPHIRE study participants.
  • Salix will be deployed across HonorHealth’s nine acute-care hospitals that provide coronary CT angiography.
  • The minimum contracted value relates to Salix Coronary Anatomy, with additional fee-per-scan Revenue possible from the Plaque and Flow modules.

Artrya Limited (ASX:AYA) has announced a five-year commercial agreement with HonorHealth, one of Arizona’s largest non-profit healthcare systems. The Perth-headquartered medical technology company says the agreement has a minimum contracted value of US$0.5 million and extends its US customer base for its Salix AI-powered cloud platform, which is used for coronary artery disease assessment.

Contract Structure and Revenue Terms

Under the agreement, Salix Coronary Anatomy will generate recurring SaaS subscription revenue. The company says additional fee-per-scan revenue will be generated from CCTA assessments performed with Salix Coronary Plaque and, following FDA clearance, Salix Coronary Flow. The US$0.5 million minimum contracted value relates only to Coronary Anatomy and excludes potential usage-based revenue from the Plaque and Flow modules. The agreement has a five-year term, with standard provisions on default, security and privacy protocols, support levels and software upgrades.

Artrya describes HonorHealth as its second-largest customer. The company has not provided estimates of coronary CT angiography scan volumes under the contract, so the revenue outcome will depend on how many scans are performed across the network.

Deployment Across HonorHealth’s Network

HonorHealth operates nine acute-care hospitals in the Phoenix and Scottsdale area, each providing specialist services including coronary CT angiography. Its HonorHealth Heart Care division provides a hub for 40 cardiac specialist offices. The system also includes 200 primary, specialist and urgent care locations across Arizona and serves a population of approximately five million people.

The system-wide integration and deployment of Salix will extend across the hospitals in the network that provide CCTA scans. Artrya says the agreement extends its US commercial footprint and provides another large reference customer for broader market adoption. The engagement followed a detailed demonstration and validation stage within HonorHealth Heart Care, led by Dr Joshua Kim, Network Director of Advanced Medical Imaging.

Beyond the Initial Deployment

HonorHealth has outlined an ambition to develop a leading CCTA program in Arizona. The initial focus is embedding Salix into clinical workflows, followed by growth in physician adoption, CCTA capacity and use of the platform’s coronary assessment modules. Over time, the two organisations intend to explore a recognised cardiovascular imaging Centre of Excellence that could support clinical evidence, education, Training and a reference model for US adoption.

HonorHealth is the primary clinical affiliate of the Arizona State University John Shufeldt School of Medicine and Medical Engineering, which the company says may create opportunities for collaborative AI research. Artrya’s chief executive, John Konstantopoulos, described the agreement as the company’s first inbound US customer and noted that it follows Huntsville Health becoming a commercial customer from the SAPPHIRE study.

The agreement also reflects the way Artrya has structured its US pipeline. The company previously described its US strategy as combining foundation customers, SAPPHIRE study participants and inbound enquiries. HonorHealth falls into the last category, and the company has linked the contract to its broader plan to establish Salix within leading healthcare organisations. Artrya’s management noted that the engagement team included technical, clinical and information technology specialists and worked through a detailed demonstration and validation stage before the contract was signed. The company describes the HonorHealth relationship as one that provides a reference site for other US health systems evaluating coronary CT angiography workflows.

Closing Perspective

The agreement adds a large health system to Artrya’s US commercial roll-out, with revenue beyond the minimum value dependent on scan volumes across nine hospitals and on FDA clearance for the Plaque and Flow modules. Artrya’s immediate focus, as stated in its announcement, is successful implementation and clinical adoption across the HonorHealth network. Future updates on deployment progress, module clearances and the proposed Centre of Excellence will indicate how the contract develops.